Can phenotypic activity be predicted without experimental readouts?

summary

Video file (mp4)

The gist

The gist The molecular encoders CLOOME and CellCLIP show no clear advantage over plain physicochemical descriptors once leakage and toxicity confounds are controlled for, suggesting they should not

In short

Molecular encoders like CLOOME and CellCLIP were tested to predict cellular phenotypic activity without running expensive Cell Painting assays. When controlling for data leakage and toxicity correlation, these encoders showed no clear advantage over standard physicochemical descriptors. The study concludes that these models are not yet reliable surrogates for phenotypic drug discovery.

Key concepts

Molecular Encoders (CLOOME/CellCLIP)
These are AI models trained on paired data linking molecules to their cellular morphology or activity. They aim to predict a compound's effect on cells based solely on its molecular structure, bypassing the need for physical experiments like Cell Painting.
Leakage Control
This refers to preventing the model from cheating by using information it shouldn't have access to during training. The study specifically controlled for 'leakage across an encoder's own pretraining boundary,' ensuring the models truly generalize rather than just memorizing training data patterns.
Toxicity Correlation
This is a confounding factor where the model might confuse general toxicity with specific phenotypic activity. The researchers controlled for this by generating toxicity labels separately from activity labels, ensuring that performance gains weren't simply due to predicting compounds that are inherently toxic rather than biologically active.

Terminology used across episodes

This episode discusses

The paper

Can phenotypic activity be predicted without experimental readouts? · Read on arXiv

Télio Cropsal, Rocío Mercado

Chalmers University of Technology · University of Gothenburg

Molecular encoders contrastively pretrained on paired molecule-morphology data, such as CLOOME and CellCLIP, have been proposed as cheap surrogates for phenotypic prediction, avoiding the need to run a Cell Painting assay. We evaluate this idea for these molecular encoders under a protocol designed to control for two confounds that can inflate apparent performance: leakage across an encoder's own pretraining boundary, and the correlation between phenotypic activity and cytotoxicity. Testing six representations, including a non-pretrained MLP control matching CLOOME's input and layer count, on two distinct Cell Painting screens, we find that once these confounds are controlled for, the pretrained molecular encoders show no clear advantage over plain physicochemical descriptors, and that toxicity is generally easier to predict than phenotypic activity across representations. Our results suggest leakage-aware, confound-controlled evaluation should be standard practice before phenotype-pretrained encoders are trusted as surrogates for phenotypic drug discovery.

Transcript

Introduction to the show: ident: AI Radio. Generated commentary on the latest Artificial Intelligence papers.

Tom: Today's paper: "Can phenotypic activity be predicted without experimental readouts?".

Jane: The gist The molecular encoders CLOOME and CellCLIP show no clear advantage over plain physicochemical descriptors once leakage and toxicity confounds are controlled for,

Tom: First, who's behind it and why it matters.

Title and authors: Jane: To get started, this paper is really asking the big question: can we predict what a molecule will do phenotypically without actually testing it in a lab first? It sets up these molecular encoders, CLOOME and CellCLIP, as potential cheap substitutes for those expensive assays.

Tom: Exactly. They are contrasting these deep learning models that learned from paired molecule-morphology data against standard structure-based methods to see if the deep learning signal is actually useful beyond just memorizing the training set.

Lu: The authors are testing this idea under a very strict protocol designed to catch two things they think usually mess up these kinds of predictions: leakage and correlation with toxicity.

Meng: Leakage sounds like when a model cheats by looking at information it shouldn't have access to, maybe from the training set itself. That’s something I worry about when deploying models.

Lalam: The paper addresses that by introducing a confound-controlled labeling scheme that statistically separates phenotypic activity from toxicity using the same validated permutation-test framework, yielding disentangled activity and toxicity labels like active, not toxic.

The paper's summary: Tom: So what they found is pretty direct: once you control for those two confounds—leakage and toxicity correlation—the molecular encoders don't show a clear advantage over plain physicochemical descriptors.

Jane: That’s a bit surprising because the models were trained on very rich data, but it suggests that the structure-based baselines are still robust enough when we look at them through this careful lens.

Lu: The specific numbers they cited on the BBBC036v1 official split showed that PhysChem and MLP had confidence intervals that were indistinguishable from CLOOME’s or CellCLIP’s own test AUROC, which was zero point five seven three and zero point five six five respectively.

Meng: So, if you look at the raw prediction scores on a specific dataset like BBBC036v1's official split, the deep learning models aren't beating the standard descriptors by much at all when you’re being rigorous about it.

Lalam: The paper also showed that CLOOME is last in terms of generalization across different Cell Painting resources, with a score of zero point six two six and no overlap with any other representation on one of the JUMP-CP chemical splits.

The paper's improvements: Jane: The authors suggest a few major improvements for how we evaluate these models, focusing heavily on making sure the results aren't just artifacts of the pretraining boundary.

Tom: They propose a leakage-aware evaluation protocol that compares chemical and batch-generalization splits against their own official pretraining-respecting split, using repeated cross-validation and Tukey’s HSD comparison for those stats.

Lu: That’s a very important methodological shift because it forces the models to prove they aren't just exploiting information from the training set to get lucky on new data, which is what they call overfitting.

Meng: I like that focus on generalization across different splits, especially when they test across two Cell Painting resources with very different scales and chemical diversity. That’s how you see if something actually works in the real world.

Lalam: Another key improvement is the creation of this confound-controlled labeling scheme, as I mentioned earlier, which statistically separates phenotypic activity from toxicity to give us those disentangled labels we need for better biological insight.

Conclusion: Jane: So to wrap up what we’ve seen in Can phenotypic activity be predicted without experimental readouts? The main conclusion is that these molecular encoders don't yet beat plain physicochemical descriptors when leakage and toxicity confounds are properly controlled.

Tom: It means we shouldn't trust them as direct surrogates for phenotypic drug discovery just yet; they need that rigorous, leakage-aware evaluation standard before they can be used to drive generation.

Lu: The authors are clear: the gap between the models and structure-based baselines that survives this controlled evaluation is due to what the contrastive pretraining actually added, not because of using richer chemical information.

Meng: For deployment purposes, if we want these models to be useful, they need to pass this kind of rigorous testing against real traffic or unseen data splits before we put them into a workflow.

Lalam: And from my view, the paper emphasizes that an encoder should be evaluated exactly how we evaluate phenotypic profiles themselves, on compounds and assays it could not have seen >

More episodes

← Home